David Brailer joins Walgreens’ board of directors
DEERFIELD, Ill. Walgreens has appointed the chairman of Health Evolution Partners to its board of directors.
The drug store chain announced Wednesday that David Brailer would join Walgreens’ board as an independent director, making him the board’s 11th member.
Brailer has served as chairman of Health Evolution Partners since 2006. Prior to joining Health Evolution Partners, he was appointed by the Bush administration as the first national health-information technology coordinator in 2004.
“David’s expertise in advancing healthcare technology on a national level, as well as his experience in supporting companies through investments that promote major change in the health system will provide us with valuable insight,” said Walgreens chairman Alan McNally. “This will be extremely important in the years ahead as technology plays an even greater role in the delivery of quality, affordable and accessible health care.”
Walgreens president and CEO Greg Wasson added, “David will be a tremendous resource to our board and our company as we help patients and payers lower healthcare costs while improving quality, outcomes and transparency through our pharmacy, health and wellness solutions.”
CRN awards dietary supplement industry executives at annual meeting
WASHINGTON Jon Benninger of Virgo Publishing, Bill Frankos of Herbalife and John Wise, chief science officer emeritus for Natural Alternatives International were each named 2010 recipients of the Council for Responsible Nutrition’s “Apple Awards” in a ceremony held last week at the association’s annual meeting, CRN announced Monday.
The award represents CRN’s highest honor and is given to executives who have shown long-term dedication and who have made considerable contributions to both CRN and the dietary supplement industry.
Benninger is the director of business development at Virgo Publishing where he is responsible for strategic planning, outreach and advocacy, content development and new business development. With 20 years in the natural products industry, he joined Virgo Publishing in 1995, and is an active member in a number of supplement industry organizations, including CRN. Virgo Publishing produces SupplySide trade shows and several publications, including “Natural Products Insider” and “Natural Products Marketplace.”
Frankos currently serves as SVP global product science, safety and compliance with Herbalife. Prior to joining Herbalife, he served as director of the division of dietary supplement programs at the center for food safety, and the applied nutrition division of the Food and Drug Administration. At the FDA, Frankos was charged with overseeing policy, budget, personnel and administration in addition to the full implementation of the Dietary Supplement Health and Education Act of 1994. Over the course of his tenure, the agency published the final rule for dietary supplement current good manufacturing practices and implemented guidance for reporting serious adverse events related to supplements.
Wise served as chief science officer for Natural Alternatives International from 2001 until his retirement in 2009. Currently, he consults for NAI and recently formed his own company, Collegiate Sports Nutrition. Prior to his work with NAI, Wise was EVP research and development with United Sciences of America. Wise, whose background includes biochemistry and microbiology, has authored and published in peer-reviewed journals on topics that include immunity and nutrition, and he has presented at more than 1,000 scientific lectures and seminars.
Axium to distribute Elaprase
LAKE MARY, Fla. Specialty pharmacy provider Axium Healthcare Pharmacy will serve as a limited distribution provider for a drug to treat a serious genetic disorder, Axium said Monday.
Axium will distribute Shire Human Genetic Therapies’ Elaprase (idursulfase), used to treat Hunter syndrome, also known as mucopolysaccharidosis II. According to the Mayo Clinic, Hunter syndrome causes chains of sugar molecules to build up in the body over time, resulting in mental deficiency and retardation, deformities, deafness and other symptoms. The juvenile-onset form of the disease typically results in death in the early teens to early 20s, while those with the late-onset form live for 20 to 60 years. It mostly affects boys.
“Axium is pleased to be granted the opportunity to be a provider of Elaprase in Puerto Rico,” Axium president and CEO Mark Montgomery said. “This selection continues to build momentum on Axium’s strong clinical programs and our investment in providing solutions for our clients.”